The year 2017 may have been a historic one for the US FDA's Center for Drug Evaluation and Research (CDER) in terms of new drugs approved, but the composition of the novel product class remained relatively consistent compared with recent years.
New drugs with priority review, orphan status all took a small dip from 2016, as did the first-cycle approval rate.





